Vaxcyte, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $59.40
- 52-Week Range
- $42.40 – $90.75
- Market Cap
- $9.26B
- P/E (TTM)
- —
- EPS (TTM)
- -8.05
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 3.51
- PEG Ratio
- —
- Return on Equity
- -42.68%
- Return on Assets
- -24.98%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 4.56
- Debt/Equity
- 0.09
- Total Debt
- $221.84M
- Free Cash Flow
- $-529.82M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $8.19B
Market Snapshot
About
Vaxcyte is a clinical-stage biotechnology company developing next-generation vaccines to prevent bacterial infectious diseases. The company focuses on pneumococcal, Group A Strep, and periodontitis prevention using its XpressCF cell-free protein synthesis platform. Lead candidate VAX-24 is a 24-valent pneumococcal conjugate vaccine.